RALLYBIO CORPORATION Operating Expenses
RALLYBIO CORPORATION (RLYB) reported Operating Expenses of $5.65 million for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-26
- RALLYBIO CORPORATION operating expenses for the quarter ending 2026-06-30 was $5.65M, a 44.95% decline year-over-year.
- RALLYBIO CORPORATION operating expenses for the quarter ending 2026-03-31 was $8.95M, a 9.48% decline year-over-year.
- RALLYBIO CORPORATION operating expenses for the quarter ending 2025-12-31 was $6.63M, a 43.04% decline year-over-year.
- RALLYBIO CORPORATION operating expenses for the quarter ending 2025-09-30 was $7.14M, a 42.28% decline year-over-year.
- RALLYBIO CORPORATION operating expenses for fiscal 2023 was $78.93M, a 16.27% increase from fiscal 2022.
- RALLYBIO CORPORATION operating expenses for fiscal 2022 was $67.88M, a 48.71% increase from fiscal 2021.
- RALLYBIO CORPORATION operating expenses for fiscal 2021 was $45.65M, a 80.41% increase from fiscal 2020.
- RALLYBIO CORPORATION operating expenses for fiscal 2020 was $25.30M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.65M S-4/A · filed 2026-08-26 | $14.60M S-4/A · filed 2026-08-26 | $21.23M derived: sum of 3 quarters · filed 2026-08-26 | $28.37M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $8.95M S-4 · filed 2026-07-15 | $15.58M derived: sum of 2 quarters · filed 2026-08-26 | $22.72M derived: sum of 3 quarters · filed 2026-08-26 | $32.98M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $6.63M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $13.77M derived: sum of 2 quarters · filed 2026-08-26 | $24.04M derived: sum of 3 quarters · filed 2026-08-26 | $33.92M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $7.14M 10-Q · filed 2025-11-06 | $17.41M derived: sum of 2 quarters · filed 2026-08-26 | $27.29M 10-Q · filed 2025-11-06 | $38.93M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $10.27M S-4/A · filed 2026-08-26 | $20.15M S-4/A · filed 2026-08-26 | $31.80M derived: sum of 3 quarters · filed 2026-08-26 | $44.16M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $9.88M S-4 · filed 2026-07-15 | $21.53M derived: sum of 2 quarters · filed 2026-08-26 | $33.89M derived: sum of 3 quarters · filed 2026-08-26 | $51.23M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | $11.65M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $24.01M derived: sum of 2 quarters · filed 2026-08-26 | $41.34M derived: sum of 3 quarters · filed 2026-08-26 | $61.13M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $12.37M 10-Q · filed 2025-11-06 | $29.70M derived: sum of 2 quarters · filed 2025-11-06 | $49.49M 10-Q · filed 2025-11-06 | $70.60M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $17.33M 10-Q · filed 2025-08-07 | $37.12M 10-Q · filed 2025-08-07 | $58.23M derived: sum of 3 quarters · filed 2025-08-07 | $77.60M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $19.79M 10-Q · filed 2025-05-08 | $40.90M derived: sum of 2 quarters · filed 2025-05-08 | $60.26M derived: sum of 3 quarters · filed 2025-05-08 | $80.34M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $21.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $40.48M derived: sum of 2 quarters · filed 2025-03-13 | $60.56M derived: sum of 3 quarters · filed 2025-03-13 | $78.93M 10-K · filed 2025-03-13 |
| 2023-09-30 | $19.36M 10-Q · filed 2024-11-07 | $39.45M derived: sum of 2 quarters · filed 2024-11-07 | $57.82M 10-Q · filed 2024-11-07 | $74.91M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $20.08M 10-Q · filed 2024-08-08 | $38.46M 10-Q · filed 2024-08-08 | $55.55M derived: sum of 3 quarters · filed 2024-08-08 | $74.41M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $18.37M 10-Q · filed 2024-05-09 | $35.47M derived: sum of 2 quarters · filed 2024-05-09 | $54.33M derived: sum of 3 quarters · filed 2024-05-09 | $71.94M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $17.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $35.95M derived: sum of 2 quarters · filed 2024-03-12 | $53.57M derived: sum of 3 quarters · filed 2024-03-12 | $67.88M 10-K · filed 2024-03-12 |
| 2022-09-30 | $18.86M 10-Q · filed 2023-11-09 | $36.48M derived: sum of 2 quarters · filed 2023-11-09 | $50.79M 10-Q · filed 2023-11-09 | $63.11M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $17.61M 10-Q · filed 2023-08-08 | $31.93M 10-Q · filed 2023-08-08 | $44.25M derived: sum of 3 quarters · filed 2023-08-08 | $54.23M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $14.32M 10-Q · filed 2023-05-09 | $26.63M derived: sum of 2 quarters · filed 2023-05-09 | $36.61M derived: sum of 3 quarters · filed 2023-05-09 | $47.14M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $12.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $22.29M derived: sum of 2 quarters · filed 2023-03-06 | $32.82M derived: sum of 3 quarters · filed 2023-03-06 | $45.65M 10-K · filed 2023-03-06 |
| 2021-09-30 | $9.98M 10-Q · filed 2022-11-07 | $20.51M derived: sum of 2 quarters · filed 2022-11-07 | $33.34M 10-Q · filed 2022-11-07 | $43.42M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $10.53M 10-Q · filed 2022-08-08 | $23.35M 10-Q · filed 2022-08-08 | $33.44M derived: sum of 3 quarters · filed 2022-08-08 | $40.15M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $12.82M 10-Q · filed 2022-05-10 | $22.91M derived: sum of 2 quarters · filed 2022-05-10 | $29.62M derived: sum of 3 quarters · filed 2022-05-10 | $34.28M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $10.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $16.80M derived: sum of 2 quarters · filed 2022-03-15 | $21.46M derived: sum of 3 quarters · filed 2022-03-15 | $25.30M 10-K · filed 2022-03-15 |
| 2020-09-30 | $6.71M 10-Q · filed 2021-11-10 | $11.37M derived: sum of 2 quarters · filed 2021-11-10 | $15.22M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $4.66M 10-Q · filed 2021-09-09 | $8.51M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |